Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer

International Journal of Colorectal Disease

Volumn 28, Issue 1, 2013, Pages 25-33

  Hong, Xinqiang ^a   Dong, Tiangen ^a   Hu, Jianwei ^a   Yi, Tuo ^a   Li, Wenxiang ^a   Zhang, Zhen ^a   Lin, Shengli ^a   Niu, Weixin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Carcinoembryonic antigen; Colonic neoplasm; Dendritic cell; Toll like receptor; Vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 12; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL ACTIVITY; CELL MATURATION; COLON CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR IMMUNITY; VACCINATION;

ANIMALS; BIOLOGICAL MARKERS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; INTERLEUKIN-12; MALE; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 84872609726     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1530-7     Document Type: Article

References (28)

1. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296. doi: 10.1146/annurev.iy.09.040191. 001415
2. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475-480. doi: 10.1038/nm1039nm1039
3. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296-306. doi: 10.1038/nri1592
4. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5(1):7-10. doi: 10.1038/ni0104-7ni0104-7
5. Proudfoot O, Pouniotis D, Sheng KC, Loveland BE, Pietersz GA (2007) Dendritic cell vaccination. Expert Rev Vaccines 6(4):617-633. doi: 10.1586/14760584.6.4.617
6. Mosolits S, Ullenhag G, Mellstedt H (2005) Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 16(6):847-862. doi: 10.1093/annonc/mdi192
7. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I (2007) Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 13(44):5822-5831
8. Adema GJ (2009) Dendritic cells from bench to bedside and back. Immunol Lett 122(2):128-130. doi: 10.1016/j.imlet.2008.11.017
9. Sporri R, Reis e Sousa C (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 6(2):163-170. doi: 10.1038/ni1162
10. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449(7161):419-426. doi: 10.1038/nature06175
11. Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117(5):1195-1203. doi: 10.1172/JCI31205
12. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987-995. doi: 10.1038/ni1112ni1112
13. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6(8):769-776. doi: 10.1038/ni1223
14. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP (2006) Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood 108(2):544-550. doi: 10.1182/blood-2005-10-4015
15. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5(5):344-366
16. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ (1998) Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58(7):1469-1477
17. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176(6):1693-1702
18. Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW (2002) Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 62(17):5058-5064
19. Eades-Perner AM, van der Putten H, Hirth A, Thompson J, Neumaier M, von Kleist S, Zimmermann W (1994) Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 54(15):4169-4176
20. Muders M, Ghoreschi K, Suckfuell M, Zimmermann W, Enders G (2003) Studies on the immunogenicity of hCEA in a transgenic mouse model. Int J Colorectal Dis 18(2):153-159. doi: 10.1007/s00384-002-0421-8
21. Hasegawa T, Isobe K, Tsuchiya Y, Oikawa S, Nakazato H, Ikezawa H, Nakashima I, Shimokata K (1991) Establishment and characterisation of human carcinoembryonic antigen transgenic mice. Br J Cancer 64(4):710-714
22. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16):4677-4685. doi: 10.1158/1078-0432.CCR-07- 0776
23. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245-252. doi: 10.1038/32588
24. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54(3):187-207. doi: 10.1007/s00262-004-0560-6
25. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ, Yamaue H (2007) Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 120(3):585-593. doi: 10.1002/ijc.22298
26. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293-299. doi: 10.1038/86297
27. van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27(1):49-55. doi: 10.1016/j.it.2005.11.005
28. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239(1):178-196. doi: 10.1111/j.1600-065X.2010.00978.x